INmune Bio Inc. (INMB)
Nasdaq: INMB · Biological Products, (No Diagnostic Substances) · Boca Raton, FL · filing with the SEC since 2017
Who owns INmune Bio Inc.
As filed with the SECHolders of 5% or more
1
Highbridge Capital Management, LLC holds 5.2% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Aug 14, 2025 says.
Directors and officers
9
report now, of 12 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Highbridge Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share
CVI Investments, Inc.
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.5% in Jul 2, 2025
Kupperman Harris
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7.2% in Apr 10, 2025
What INMB reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 30, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.